CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Selpercatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05468164
NCT05468164Phase 1Completed

An Open-Label, Randomized, Crossover Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Single-Dose Pharmacokinetics of LOXO-292 in Healthy Adult Subjects

Eli Lilly and Company·interventional·Posted Jul 21, 2022·Updated Sep 19, 2025

In Brief

A Phase 1 clinical trial evaluating Selpercatinib and Omeprazole for Healthy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The main purpose of this study is to assess the effect of food on how fast selpercatinib gets into the bloodstream and how long it takes the body to remove it after a high-fat meal, and the effect of a change in gastric pH after multiple doses of omeprazole on how fast selpercatinib gets into the bloodstream and how long it takes the body to remove it when administered under fasted and fed conditions in healthy participants. The study will also evaluate the safety and tolerability of selpercatinib in healthy participants. The study will last up to 33 days excluding the screening period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJul 21, 2022
Enrollment StartMay 31, 2018
Primary CompletionSep 13, 2018
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.9 years ago

Interventions

Selpercatinibdrug

Administered orally

Omeprazoledrug

Administered orally